Predictive Factors for Survival in Aggressive Meningiomas
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
About this trial
The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient operated for atypical (grade 2) meningioma; or
Patient operated for anaplastic (grade 3) meningioma;
Timeframe for surgery, 1999-2019
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
Biological biomarker assessment
Diagnostic testIHC, PCR, NGS, methylome
Treatment groups
250 Participants
are divided into 1 treatment groupGroup A: Biological biomarker assessmentOther 1 intervention
Trial outcomes
Primary outcomes
1
Recurrence-free survival (RFS)
Correlation from biomolecular data and RFS
Time frame
5 years on averageSecondary outcomes
1
Overall survival (OS)
Correlation from biomolecular data and OS
Time frame
5 years on averageSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov